Search research articles
Contact Us
Filters
Showing results (41-50 of 83) with videos related to
Page
of 9
Sort By:
British Journal of Haematology
|
April 2, 2015
Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas
Felipe Samaniego, Fredrick Hagemeister, Jorge E Romaguera, et al.
Leukemia & Lymphoma
|
April 5, 2018
Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy
Chelsea C Pinnix, Andrew Wirth, Sarah A Milgrom, et al.
Leukemia & Lymphoma
|
August 24, 2011
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results
Paolo Anderlini, Rima M Saliba, Celina Ledesma, et al.
The Oncologist
|
August 16, 2018
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
Winnie S Liang, Jo-Anne Vergilio, Bodour Salhia, et al.
Leukemia & Lymphoma
|
August 10, 2017
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma
Bei Hu, Anas Younes, Jason R Westin, et al.
British Journal of Haematology
|
March 29, 2019
Lenalidomide plus rituximab (R<sup>2</sup> ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial
Melody R Becnel, Loretta J Nastoupil, Felipe Samaniego, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 26, 2017
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen, Pier Luigi Zinzani, Michelle A Fanale, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 12, 2016
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
Paolo Anderlini, Rima M Saliba, Celina Ledesma, et al.
British Journal of Haematology
|
March 25, 2017
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study
Loretta J Nastoupil, Peter McLaughlin, Lei Feng, et al.
Radiation Oncology (London, England)
|
September 27, 2015
Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma
Bassem Youssef, JoAnn Shank, Jay P Reddy, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 83) with videos related to
Sort By:
Page
of 9
British Journal of Haematology
|
April 2, 2015
Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas
Felipe Samaniego, Fredrick Hagemeister, Jorge E Romaguera, et al.
Leukemia & Lymphoma
|
April 5, 2018
Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy
Chelsea C Pinnix, Andrew Wirth, Sarah A Milgrom, et al.
Leukemia & Lymphoma
|
August 24, 2011
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results
Paolo Anderlini, Rima M Saliba, Celina Ledesma, et al.
The Oncologist
|
August 16, 2018
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
Winnie S Liang, Jo-Anne Vergilio, Bodour Salhia, et al.
Leukemia & Lymphoma
|
August 10, 2017
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma
Bei Hu, Anas Younes, Jason R Westin, et al.
British Journal of Haematology
|
March 29, 2019
Lenalidomide plus rituximab (R<sup>2</sup> ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial
Melody R Becnel, Loretta J Nastoupil, Felipe Samaniego, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 26, 2017
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen, Pier Luigi Zinzani, Michelle A Fanale, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 12, 2016
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
Paolo Anderlini, Rima M Saliba, Celina Ledesma, et al.
British Journal of Haematology
|
March 25, 2017
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study
Loretta J Nastoupil, Peter McLaughlin, Lei Feng, et al.
Radiation Oncology (London, England)
|
September 27, 2015
Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma
Bassem Youssef, JoAnn Shank, Jay P Reddy, et al.
Page
of 9